Farletuzumab in epithelial ovarian carcinoma

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Choi J, Yip-Schneider M, Albertin F, The Effect of Doxorubicin on MEK-ERK Signaling Predicts Its Efficacy in HCC. J Surg Res 2008;150:219-26
   PubMed Web of Science ®Google Scholar
• Bagnoli M, Canevari S, Figini M, A step further in understanding the biology of the folate receptor in ovarian carcinoma. Gynecol Oncol 2003;88(1 Pt 2):S140-4
   Google Scholar
• Miotti S, Bagnoli M, Ottone F, Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Biochem 1997;65(4):479-91
   PubMed Web of Science ®Google Scholar
• Kalli KR, Oberg AL, Keeney GL, Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108(3):619-26
   PubMed Web of Science ®Google Scholar
• Toffoli G, Cernigoi C, Russo A, Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74(2):193-8
   PubMed Web of Science ®Google Scholar
• Chung MK, Han SS, Roh JK. Synergistic embryotoxicity of combination pyrimethamine and folic acid in rats. Reprod Toxicol 1993;7(5):463-8
   PubMed Web of Science ®Google Scholar
• Bottero F, Tomassetti A, Canevari S, Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 1993;53(23):5791-6
   PubMed Web of Science ®Google Scholar
• Figini M, Ferri R, Mezzanzanica D, Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther 2003;10(12):1018-25
   PubMed Web of Science ®Google Scholar
• Buist MR, Kenemans P, den Hollander W, Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients. Cancer Res 1993;53(22):5413-8
   PubMed Web of Science ®Google Scholar
• Buist MR, Kenemans P, van Kamp GJ, Haisma HJ. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother 1995;40(1):24-30
   PubMed Web of Science ®Google Scholar
• Molthoff CF, Buist MR, Kenemans P, Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J Nucl Med 1992;33(11):2000-5
   PubMed Web of Science ®Google Scholar
• Molthoff CF, Prinssen HM, Kenemans P, Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer 1997;80(12 Suppl):2712-20
   PubMed Web of Science ®Google Scholar
• van Zanten-Przybysz I, Molthoff C, Gebbinck JK, Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J Cancer Res Clin Oncol 2002;128(9):484-92
   PubMed Web of Science ®Google Scholar
• van Zanten-Przybysz I, Molthoff CF, Roos JC, Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int J Cancer 2001;92(1):106-14
   PubMed Web of Science ®Google Scholar
• Canevari S, Mezzanzanica D, Mazzoni A, Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother 1995;4(5):423-7
   PubMedGoogle Scholar
• Crippa F, Bolis G, Seregni E, Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 1995;31A(5):686-90
   PubMed Web of Science ®Google Scholar
• Garin-Chesa P, Campbell I, Saigo PE, Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993;142(2):557-67
   PubMed Web of Science ®Google Scholar
• Ebel W, Routhier EL, Foley B, Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007;7:6
   PubMedGoogle Scholar
• Nicolaides NC, Ebel W, Kline B, Morphogenics as a tool for target discovery and drug development. Ann NY Acad Sci 2005;1059:86-96
   PubMed Web of Science ®Google Scholar
• Smith-Jones PM, Pandit-Taskar N, Cao W, Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 2008;35(3):343-51
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bicher A, Coleman RL, Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse. J Clin Oncol 2008;26: abstract 5500
   Web of Science ®Google Scholar
• Coleman RL, Armstrong DK, White AJ, Farletuzumab, A novel monoclonal antibody against folate receptor-alpha, exhibits clnical efficacy in platinum-sensitive 1st relapse of ovarian cancer subjects. Proc Eur Soc Gynecol Oncol 2009: abstract #90
   Google Scholar
• du Bois A, Quinn M, Thigpen T, 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl 8):viii7-12
   PubMedGoogle Scholar
• Pfisterer J, Plante M, Vergote I, Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: an Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-707
   PubMed Web of Science ®Google Scholar